Decitabine and vorinostat combined with fludarabine, cytarabine, and granulocyte colony-stimulating factor were reported to treat 35 pediatric patients with relapsed or refractory AML with an overall response rate of 54%, as described in Table 3.101. Here, CSF3 is linked to acute myeloid leukemia.